Table 1 Open in new tab Important...

Parameter	Mean	Reference
Baseline characteristics
Age	75	^a
Female gender	55.9%	^a
CHA2DS2-VASc score	3.45	^a
Prevalence unknown AF	3.0%	21
Persistent AF	0.5%	^a
Paroxysmal AF	2.5%	^a
ECG recordings per subject	26	Assumption
Probabilities
Mortality stroke (CHADS₂ = 2)	0.269	8
Yearly spontaneous detection of asymptomatic AF (base case)	5%	Assumption
AF detected after stroke	88.2%	14
Intracranial bleedings	0.6	34
Major bleedings warfarin	5.2	24
Major bleedings no OAC	2.3	34
Yearly stroke risk in AF
With apixaban
CHA₂DS₂-VASc 3	0.012	10,24,34
CHA₂DS₂-VASc 4	0.018	10,24,34
CHA₂DS₂-VASc 5	0.027	10,24,34
CHA₂DS₂-VASc 6	0.037	10,24,34
With no OAC
CHA₂DS₂-VASc 3	0.036	34
CHA₂DS₂-VASc 4	0.054	34
CHA₂DS₂-VASc 5	0.083	34
CHA₂DS₂-VASc 6	0.113	34
Proportion treated with (AF patients)
Warfarin	0%	Base case
Apixaban	93%	Base case
Aspirin	0%	Base case
Costs (€)
Screening hand-held ECG	106	37
Invitation screening	2	37
24-h ECG	266	^b
Apixaban (yearly)	844	28
Stroke ≤1 year	18 172	36
Stroke >1 year	4336	36
Severe bleeding	2927	38
Minor bleeding	40	Assumption
Quality of life
Age 70–79	0.794	39
Age 80–88	0.733	39
QALY-loss ischaemic stroke (yearly)	0.15	6
QALY-loss bleeding stroke (yearly)	0.30	6

Parameter

Mean

Reference

Baseline characteristics

Age

Female gender

55.9%

CHA2DS2-VASc score

3.45

Prevalence unknown AF

3.0%

Persistent AF

0.5%

Paroxysmal AF

2.5%

ECG recordings per subject

Assumption

Probabilities

Mortality stroke (CHADS₂ = 2)

0.269

Yearly spontaneous detection of asymptomatic AF (base case)

Assumption

AF detected after stroke

88.2%

Intracranial bleedings

0.6

Major bleedings warfarin

5.2

Major bleedings no OAC

2.3

Yearly stroke risk in AF

With apixaban

CHA₂DS₂-VASc 3

0.012

10,24,34

CHA₂DS₂-VASc 4

0.018

10,24,34

CHA₂DS₂-VASc 5

0.027

10,24,34

CHA₂DS₂-VASc 6

0.037

10,24,34

With no OAC

CHA₂DS₂-VASc 3

0.036

CHA₂DS₂-VASc 4

0.054

CHA₂DS₂-VASc 5

0.083

CHA₂DS₂-VASc 6

0.113

Proportion treated with (AF patients)

Warfarin

Base case

Apixaban

93%

Base case

Aspirin

Base case

Costs (€)

Screening hand-held ECG

106

Invitation screening

24-h ECG

266

Apixaban (yearly)

844

Stroke ≤1 year

18 172

Stroke >1 year

4336

Severe bleeding

2927

Minor bleeding

Assumption

Quality of life

Age 70–79

0.794

Age 80–88

0.733

QALY-loss ischaemic stroke (yearly)

0.15

QALY-loss bleeding stroke (yearly)

0.30

Parameter	Mean	Reference
Baseline characteristics
Age	75	^a
Female gender	55.9%	^a
CHA2DS2-VASc score	3.45	^a
Prevalence unknown AF	3.0%	21
Persistent AF	0.5%	^a
Paroxysmal AF	2.5%	^a
ECG recordings per subject	26	Assumption
Probabilities
Mortality stroke (CHADS₂ = 2)	0.269	8
Yearly spontaneous detection of asymptomatic AF (base case)	5%	Assumption
AF detected after stroke	88.2%	14
Intracranial bleedings	0.6	34
Major bleedings warfarin	5.2	24
Major bleedings no OAC	2.3	34
Yearly stroke risk in AF
With apixaban
CHA₂DS₂-VASc 3	0.012	10,24,34
CHA₂DS₂-VASc 4	0.018	10,24,34
CHA₂DS₂-VASc 5	0.027	10,24,34
CHA₂DS₂-VASc 6	0.037	10,24,34
With no OAC
CHA₂DS₂-VASc 3	0.036	34
CHA₂DS₂-VASc 4	0.054	34
CHA₂DS₂-VASc 5	0.083	34
CHA₂DS₂-VASc 6	0.113	34
Proportion treated with (AF patients)
Warfarin	0%	Base case
Apixaban	93%	Base case
Aspirin	0%	Base case
Costs (€)
Screening hand-held ECG	106	37
Invitation screening	2	37
24-h ECG	266	^b
Apixaban (yearly)	844	28
Stroke ≤1 year	18 172	36
Stroke >1 year	4336	36
Severe bleeding	2927	38
Minor bleeding	40	Assumption
Quality of life
Age 70–79	0.794	39
Age 80–88	0.733	39
QALY-loss ischaemic stroke (yearly)	0.15	6
QALY-loss bleeding stroke (yearly)	0.30	6

Table 1

Open in new tab

Important parameters in the model

Parameter	Mean	Reference
Baseline characteristics
Age	75	^a
Female gender	55.9%	^a
CHA2DS2-VASc score	3.45	^a
Prevalence unknown AF	3.0%	21
Persistent AF	0.5%	^a
Paroxysmal AF	2.5%	^a
ECG recordings per subject	26	Assumption
Probabilities
Mortality stroke (CHADS₂ = 2)	0.269	8
Yearly spontaneous detection of asymptomatic AF (base case)	5%	Assumption
AF detected after stroke	88.2%	14
Intracranial bleedings	0.6	34
Major bleedings warfarin	5.2	24
Major bleedings no OAC	2.3	34
Yearly stroke risk in AF
With apixaban
CHA₂DS₂-VASc 3	0.012	10,24,34
CHA₂DS₂-VASc 4	0.018	10,24,34
CHA₂DS₂-VASc 5	0.027	10,24,34
CHA₂DS₂-VASc 6	0.037	10,24,34
With no OAC
CHA₂DS₂-VASc 3	0.036	34
CHA₂DS₂-VASc 4	0.054	34
CHA₂DS₂-VASc 5	0.083	34
CHA₂DS₂-VASc 6	0.113	34
Proportion treated with (AF patients)
Warfarin	0%	Base case
Apixaban	93%	Base case
Aspirin	0%	Base case
Costs (€)
Screening hand-held ECG	106	37
Invitation screening	2	37
24-h ECG	266	^b
Apixaban (yearly)	844	28
Stroke ≤1 year	18 172	36
Stroke >1 year	4336	36
Severe bleeding	2927	38
Minor bleeding	40	Assumption
Quality of life
Age 70–79	0.794	39
Age 80–88	0.733	39
QALY-loss ischaemic stroke (yearly)	0.15	6
QALY-loss bleeding stroke (yearly)	0.30	6

Parameter	Mean	Reference
Baseline characteristics
Age	75	^a
Female gender	55.9%	^a
CHA2DS2-VASc score	3.45	^a
Prevalence unknown AF	3.0%	21
Persistent AF	0.5%	^a
Paroxysmal AF	2.5%	^a
ECG recordings per subject	26	Assumption
Probabilities
Mortality stroke (CHADS₂ = 2)	0.269	8
Yearly spontaneous detection of asymptomatic AF (base case)	5%	Assumption
AF detected after stroke	88.2%	14
Intracranial bleedings	0.6	34
Major bleedings warfarin	5.2	24
Major bleedings no OAC	2.3	34
Yearly stroke risk in AF
With apixaban
CHA₂DS₂-VASc 3	0.012	10,24,34
CHA₂DS₂-VASc 4	0.018	10,24,34
CHA₂DS₂-VASc 5	0.027	10,24,34
CHA₂DS₂-VASc 6	0.037	10,24,34
With no OAC
CHA₂DS₂-VASc 3	0.036	34
CHA₂DS₂-VASc 4	0.054	34
CHA₂DS₂-VASc 5	0.083	34
CHA₂DS₂-VASc 6	0.113	34
Proportion treated with (AF patients)
Warfarin	0%	Base case
Apixaban	93%	Base case
Aspirin	0%	Base case
Costs (€)
Screening hand-held ECG	106	37
Invitation screening	2	37
24-h ECG	266	^b
Apixaban (yearly)	844	28
Stroke ≤1 year	18 172	36
Stroke >1 year	4336	36
Severe bleeding	2927	38
Minor bleeding	40	Assumption
Quality of life
Age 70–79	0.794	39
Age 80–88	0.733	39
QALY-loss ischaemic stroke (yearly)	0.15	6
QALY-loss bleeding stroke (yearly)	0.30	6

OAC, oral anticoagulant; AF, Atrial fibrillation; ECG, Electrocardiography; QALY, Quality-adjusted life-year.

^aUnpublished data from the STROKESTOP study.

^bCost at Department of Cardiology, Linköping University Hospital.

This Feature Is Available To Subscribers Only